Selected research
Industry Research
GLP-1 Drugs Industry Research Report 2026
Market perspective
The global GLP-1 Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for GLP-1 Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for GLP-1 Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for GLP-1 Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of GLP-1 Drugs include AstraZeneca, Eli Lilly, GSK, Novo Nordisk, Sanofi, Shanghai Renhui Biopharmaceutical, Sino Biopharm and Huadong Medicine, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global GLP-1 Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
GLP-1 Drugs Market by Company
AstraZeneca
Eli Lilly
GSK
Novo Nordisk
Sanofi
Shanghai Renhui Biopharmaceutical
Sino Biopharm
Huadong Medicine
GLP-1 Drugs Segment by Type
Albiglutide
Exenatide
Beinaglutide
Dulaglutide
Liraglutide
Lixisenatide
Semaglutide
GLP-1 Drugs Segment by Application
Type 2 Diabetes
Obesity
GLP-1 Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GLP-1 Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of GLP-1 Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GLP-1 Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of GLP-1 Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of GLP-1 Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of GLP-1 Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Albiglutide
- Exenatide
- Beinaglutide
- Dulaglutide
- Liraglutide
- Lixisenatide
- Semaglutide
Applications
- Type 2 Diabetes
- Obesity
Companies covered
- AstraZeneca
- Eli Lilly
- GSK
- Novo Nordisk
- Sanofi
- Shanghai Renhui Biopharmaceutical
- Sino Biopharm
- Huadong Medicine
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global GLP-1 Drugs Market Size (2021-2032)
- 2.2.2 Global GLP-1 Drugs Sales (2021-2032)
- 2.2.3 Global GLP-1 Drugs Market Average Price (2021-2032)
- 2.3 GLP-1 Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Albiglutide
- 2.3.3 Exenatide
- 2.3.4 Beinaglutide
- 2.3.5 Dulaglutide
- 2.3.6 Liraglutide
- 2.3.7 Lixisenatide
- 2.3.8 Semaglutide
- 2.4 GLP-1 Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Type 2 Diabetes
- 2.4.3 Obesity
3 Market Competitive Landscape by Manufacturers
- 3.1 Global GLP-1 Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global GLP-1 Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global GLP-1 Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global GLP-1 Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global GLP-1 Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of GLP-1 Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of GLP-1 Drugs, Product Type & Application
- 3.8 Global Manufacturers of GLP-1 Drugs, Established Date
- 3.9 Global GLP-1 Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 AstraZeneca
- 4.1.1 AstraZeneca Company Information
- 4.1.2 AstraZeneca Business Overview
- 4.1.3 AstraZeneca GLP-1 Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 AstraZeneca GLP-1 Drugs Product Portfolio
- 4.1.5 AstraZeneca Recent Developments
- 4.2 Eli Lilly
- 4.2.1 Eli Lilly Company Information
- 4.2.2 Eli Lilly Business Overview
- 4.2.3 Eli Lilly GLP-1 Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Eli Lilly GLP-1 Drugs Product Portfolio
- 4.2.5 Eli Lilly Recent Developments
- 4.3 GSK
- 4.3.1 GSK Company Information
- 4.3.2 GSK Business Overview
- 4.3.3 GSK GLP-1 Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 GSK GLP-1 Drugs Product Portfolio
- 4.3.5 GSK Recent Developments
- 4.4 Novo Nordisk
- 4.4.1 Novo Nordisk Company Information
- 4.4.2 Novo Nordisk Business Overview
- 4.4.3 Novo Nordisk GLP-1 Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Novo Nordisk GLP-1 Drugs Product Portfolio
- 4.4.5 Novo Nordisk Recent Developments
- 4.5 Sanofi
- 4.5.1 Sanofi Company Information
- 4.5.2 Sanofi Business Overview
- 4.5.3 Sanofi GLP-1 Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Sanofi GLP-1 Drugs Product Portfolio
- 4.5.5 Sanofi Recent Developments
- 4.6 Shanghai Renhui Biopharmaceutical
- 4.6.1 Shanghai Renhui Biopharmaceutical Company Information
- 4.6.2 Shanghai Renhui Biopharmaceutical Business Overview
- 4.6.3 Shanghai Renhui Biopharmaceutical GLP-1 Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Shanghai Renhui Biopharmaceutical GLP-1 Drugs Product Portfolio
- 4.6.5 Shanghai Renhui Biopharmaceutical Recent Developments
- 4.7 Sino Biopharm
- 4.7.1 Sino Biopharm Company Information
- 4.7.2 Sino Biopharm Business Overview
- 4.7.3 Sino Biopharm GLP-1 Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Sino Biopharm GLP-1 Drugs Product Portfolio
- 4.7.5 Sino Biopharm Recent Developments
- 4.8 Huadong Medicine
- 4.8.1 Huadong Medicine Company Information
- 4.8.2 Huadong Medicine Business Overview
- 4.8.3 Huadong Medicine GLP-1 Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Huadong Medicine GLP-1 Drugs Product Portfolio
- 4.8.5 Huadong Medicine Recent Developments
5 Global GLP-1 Drugs Market Scenario by Region
- 5.1 Global GLP-1 Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global GLP-1 Drugs Sales by Region: 2021-2032
- 5.2.1 Global GLP-1 Drugs Sales by Region: 2021-2026
- 5.2.2 Global GLP-1 Drugs Sales by Region: 2027-2032
- 5.3 Global GLP-1 Drugs Revenue by Region: 2021-2032
- 5.3.1 Global GLP-1 Drugs Revenue by Region: 2021-2026
- 5.3.2 Global GLP-1 Drugs Revenue by Region: 2027-2032
- 5.4 North America GLP-1 Drugs Market Facts & Figures by Country
- 5.4.1 North America GLP-1 Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America GLP-1 Drugs Sales by Country (2021-2032)
- 5.4.3 North America GLP-1 Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe GLP-1 Drugs Market Facts & Figures by Country
- 5.5.1 Europe GLP-1 Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe GLP-1 Drugs Sales by Country (2021-2032)
- 5.5.3 Europe GLP-1 Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific GLP-1 Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific GLP-1 Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific GLP-1 Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific GLP-1 Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America GLP-1 Drugs Market Facts & Figures by Country
- 5.7.1 South America GLP-1 Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America GLP-1 Drugs Sales by Country (2021-2032)
- 5.7.3 South America GLP-1 Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa GLP-1 Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa GLP-1 Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa GLP-1 Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa GLP-1 Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global GLP-1 Drugs Sales by Type (2021-2032)
- 6.1.1 Global GLP-1 Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global GLP-1 Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global GLP-1 Drugs Revenue by Type (2021-2032)
- 6.2.1 Global GLP-1 Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global GLP-1 Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global GLP-1 Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global GLP-1 Drugs Sales by Application (2021-2032)
- 7.1.1 Global GLP-1 Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global GLP-1 Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global GLP-1 Drugs Revenue by Application (2021-2032)
- 7.2.1 Global GLP-1 Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global GLP-1 Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global GLP-1 Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 GLP-1 Drugs Value Chain Analysis
- 8.1.1 GLP-1 Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 GLP-1 Drugs Production Mode & Process
- 8.2 GLP-1 Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 GLP-1 Drugs Distributors
- 8.2.3 GLP-1 Drugs Customers
9 Global GLP-1 Drugs Analyzing Market Dynamics
- 9.1 GLP-1 Drugs Industry Trends
- 9.2 GLP-1 Drugs Industry Drivers
- 9.3 GLP-1 Drugs Industry Opportunities and Challenges
- 9.4 GLP-1 Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst